Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Abraxane, Metformin and Dietary Supplement in Unresectable Pancreatic Cancer
NCT02336087Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Mar 2016
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gemcitabine, nab-paclitaxel and liquid metformin (Aspargo Labs) in pancreatic cancer (PC), sponsored by City of Hope. Primary endpoints: Feasibility up to 24 months, Compliance up to 24 months and 1 more. Started Mar 2016; status: active, not recruiting.
02
Drugs
gemcitabinenab-paclitaxelliquid metformin (Aspargo Labs)
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02336087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336087.